Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.
Cancer Prev Res (Phila). 2011 Nov;4(11):1938-44. doi: 10.1158/1940-6207.CAPR-10-0259. Epub 2011 Aug 16.
The recently published report of the SELECT evaluation of selenium and vitamin E provided strong evidence that selenium 200 μg per day in the form of selenomethionine does not protect selenium-replete men against prostate or any other cancer. This seems to refute the result of the much smaller Nutritional Prevention of Cancer (NPC) trial of selenium. Because SELECT did not test the NPC agent, it is possible that the difference between the two trials stems partly from the use of different agents: selenomethionine in SELECT, and selenized yeast in the NPC trial. One of the organic selenium forms suspected of having strong chemopreventive effects, and which may have been present in the NPC agent, is methyl selenocysteine. This study characterizes the single-dose pharmacokinetics of methyl selenocysteine.
最近发表的 SELECT 评价硒和维生素 E 的报告提供了有力的证据,表明每天以硒蛋氨酸形式摄入 200μg 的硒并不能预防硒充足的男性前列腺癌或任何其他癌症。这似乎推翻了营养预防癌症(NPC)试验中硒的结果。由于 SELECT 并未测试 NPC 试剂,因此这两项试验之间的差异可能部分源于使用不同的试剂:SELECT 中使用的是硒蛋氨酸,而 NPC 试验中使用的是硒酵母。有机硒形式之一的甲基硒代半胱氨酸被怀疑具有很强的化学预防作用,并且可能存在于 NPC 试剂中。本研究描述了甲基硒代半胱氨酸的单次剂量药代动力学特征。